ERA

Download the full-sized PDF of Novel Insights into the Role of O6-Methylguanine-DNA Methyltransferase in Glioblastoma Angiogenesis, Invasion, and ProliferationDownload the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3HH3T

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Novel Insights into the Role of O6-Methylguanine-DNA Methyltransferase in Glioblastoma Angiogenesis, Invasion, and Proliferation Open Access

Descriptions

Other title
Subject/Keyword
Proliferation
Invasion
Glioblastoma
MGMT
Angiogenesis
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Chahal, Manik
Supervisor and department
Abdulkarim, Bassam (Oncology)
Examining committee member and department
Godbout, Roseline (Oncology)
Lai, Raymond (Laboratory Medicine and Pathology)
Easaw, Jay (Medical Oncology, TBCC)
Weinfeld, Michael (Oncology)
Jean-Claude, Bertrand (Experimental Medicine, McGill)
Department
Department of Oncology
Specialization
Experimental Oncology
Date accepted
2012-08-22T15:55:21Z
Graduation date
2012-11
Degree
Doctor of Philosophy
Degree level
Doctoral
Abstract
Glioblastoma multiforme (GBM) is characterized by aberrant angiogenesis, rapid proliferation, and widespread invasion through the brain parenchyma. Thus, the prognosis for these tumors remains extremely poor despite aggressive multimodal treatment including chemotherapy with the alkylating agent temozolomide (TMZ). The expression of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) further contributes to treatment resistance by repairing tumoral alkylation damage induced by TMZ, highlighting the requirement for alternative therapeutic options. Though MGMT promoter methylation is a prognostic indicator of response to TMZ, it has also been correlated with increased rate of mutation in GBM and phenotypic alterations in other tumors. Therefore, we aimed to identify whether MGMT may play a greater role in GBM pathology and therapeutic response beyond mediation of alkylating chemotherapy resistance. We determined through gene expression profiling that MGMT expression in GBM cells induced genetic alterations in several functional pathways. Of particular interest in GBM pathology, MGMT overexpression elicited a switch of the angiogenic balance towards an anti-angiogenic profile, as determined by altered expression of vascular endothelial growth factor and its receptors. Furthermore, we established an inverse relationship between MGMT expression and invasion using MGMT overexpression and knockdown models and panels of established and patient-derived primary GBM cell lines. Importantly, our in vitro data were validated in primary GBM tumor biopsy samples showing that MGMT promoter methylation (i.e. MGMT gene silencing) was significantly associated with increased immunohistochemical expression of SPARC, a well-known marker of GBM invasion. Concurrently, in isogenic models we found that MGMT expression positively correlated with increased proliferation, consistent with the well-established theory that invasion and proliferation are mutually exclusive in GBM. Of great importance, the clinical relevance of our investigations was further demonstrated by our striking finding that decreased MGMT expression was associated with increased invasiveness following treatment with angiogenic inhibitors. Our study therefore provides new insight into the aggressiveness of GBM by highlighting potentially novel roles for the DNA repair protein MGMT. Moreover, our data suggest the potential utilization of MGMT as a biomarker for response to angiogenic inhibitors, which constitutes an important step in developing more effective therapies for patients suffering from this devastating disease.
Language
English
DOI
doi:10.7939/R3HH3T
Rights
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication
Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B. (2010). MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro-Oncology, 12(8): 822-833.

File Details

Date Uploaded
Date Modified
2014-04-29T18:09:03.123+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 8563220
Last modified: 2015:10:12 10:53:51-06:00
Filename: Chahal_Manik_Fall 2012.pdf
Original checksum: 15cb53fbae84a10d6c398af284b56ba9
Well formed: true
Valid: true
Status message: File header gives version as 1.4, but catalog dictionary gives version as 1.3
Status message: Too many fonts to report; some fonts omitted. Total fonts = 1312
File title: Microsoft Word - Manik Chahal PhD Thesis final revisions.docx
File author: Manik Chahal
Page count: 267
Activity of users you follow
User Activity Date